Bio-Techne Corporation (TECH)
Automate Your Wheel Strategy on TECH
With Tiblio's Option Bot, you can configure your own wheel strategy including TECH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TECH
- Rev/Share 7.8264
- Book/Share 12.6448
- PB 5.1112
- Debt/Equity 0.2007
- CurrentRatio 4.2167
- ROIC 0.0346
- MktCap 10070194190.0
- FreeCF/Share 1.4412
- PFCF 44.9452
- PE 128.8506
- Debt/Assets 0.1562
- DivYield 0.005
- ROE 0.0391
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | TECH | RBC Capital Mkts | Sector Perform | Outperform | -- | $73 | Sept. 3, 2025 |
| Upgrade | TECH | Citigroup | Neutral | Buy | -- | $70 | Aug. 21, 2025 |
| Resumed | TECH | Stephens | -- | Overweight | -- | $65 | July 22, 2025 |
| Initiation | TECH | TD Cowen | -- | Buy | -- | $65 | July 9, 2025 |
| Initiation | TECH | Wells Fargo | -- | Overweight | -- | $59 | May 30, 2025 |
| Downgrade | TECH | KeyBanc Capital Markets | Overweight | Sector Weight | -- | -- | April 9, 2025 |
| Initiation | TECH | Evercore ISI | -- | Outperform | -- | $75 | March 18, 2025 |
| Downgrade | TECH | Robert W. Baird | Outperform | Neutral | $88 | $68 | Feb. 19, 2025 |
News
Bio-Techne Corporation (TECH) Q2 2026 Earnings Call Transcript
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (TECH) Q2 2026 Earnings Call Transcript
Read More
TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Bio-Techne tops Q2 EPS and revenue estimates as operating margin jumps 244 bps, even with flat organic sales and a slight year-over-year revenue dip.
Read More
Techne (TECH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Techne (TECH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
CSLLY or TECH: Which Is the Better Value Stock Right Now?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Bio-Techne's Q2 Earnings on Deck: What's in Store for the Stock?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Negative
TECH is set to report Q2 results on Feb. 4, with EPS seen at 43 cents and revenues at $292M as tariffs, NIH funding and segment shifts shape outlook.
Read More
Madison Mid Cap Fund Q4 2025 Portfolio Activity
Published: January 28, 2026 by: Seeking Alpha
Sentiment: Neutral
We added four new investments to the portfolio: Bio-Techne, ServiceTitan, A.O. Smith, and MSA Safety. We sold two holdings, Trex and Microchip Technology. We trimmed our position in Amphenol during the quarter, on valuation.
Read More
Bio-Techne Corporation (TECH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (TECH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Bio-Techne Corporation (TECH) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation ( TECH ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:30 AM EST Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Tycho Peterson Tycho Peterson Presentation Tycho Peterson Okay. Great. We're going to kick it off.
Read More
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine MINNEAPOLIS and SEATTLE , Nov. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ …
Read More
Bio-Techne Corporation (TECH) Presents at Stifel 2025 Healthcare Conference Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation ( TECH ) Stifel 2025 Healthcare Conference November 11, 2025 9:20 AM EST Company Participants Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division Okay. We'll go ahead and get started.
Read More
Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation ( TECH ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division Our next session here is the management team from Bio-Techne. We're lucky to be joined by Kim Kelderman, Jim Hippel and Dave Clair.
Read More
Bio-Techne Corporation (TECH) Q1 2026 Earnings Call Transcript
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation ( TECH ) Q1 2026 Earnings Call November 5, 2025 9:00 AM EST Company Participants David Clair - VP of Investor Relations & Corporate Development Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Puneet Souda - Leerink Partners LLC, Research Division Patrick Donnelly - Citigroup Inc., Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Boucher - TD Cowen, Research Division Catherine Ramsey - Robert …
Read More
TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins.
Read More
Here's What Key Metrics Tell Us About Techne (TECH) Q1 Earnings
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Techne (TECH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
GMAB or TECH: Which Is the Better Value Stock Right Now?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
Should You Continue to Hold Bio-Techne Stock in Your Portfolio?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
TECH drives growth via acquisitions, international strength and innovation. However, it faces macro pressures and rising competition.
Read More
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
Read More
Bio-Techne Corporation (TECH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (NASDAQ:TECH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Presentation Unknown Analyst All right. Thank you, everyone, for joining today.
Read More
Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (NASDAQ:TECH ) Baird Global Healthcare Conference 2025 September 9, 2025 9:05 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst Catherine Schulte.
Read More
Bio-Techne Corporation (TECH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (NASDAQ:TECH ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Kim Kelderman - CEO, President & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Great. Good morning.
Read More
Bio-Techne to Present at Upcoming Investor Conferences
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference September 3, 2025 10:15 AM EDT Baird 2025 Global Healthcare Conference September 9, 2025 9:05 AM EDT Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and …
Read More
Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Techne Corporation (NASDAQ:TECH ) Q4 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants David Clair - VP of Investor Relations & Corporate Development James T. Hippel - Executive VP of Finance & CFO Kim Kelderman - CEO, President & Director Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Kyle Boucher - TD Cowen, Research Division Matthew Richard Larew - William Blair & Company …
Read More
Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
Read More
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Negative
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
Read More
Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell
Published: July 28, 2025 by: Seeking Alpha
Sentiment: Negative
Bio-Techne Corporation is a market leader in life science reagents, well positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring revenue, near-term risks from NIH funding cuts and U.S.-China tariffs are not fully priced in. My DCF analysis suggests TECH stock is overvalued, with a fair value of $48 per share versus current high multiples; I initiate with a Sell rating.
Read More
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
MINNEAPOLIS , July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results.
Read More
INCY or TECH: Which Is the Better Value Stock Right Now?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology
Published: July 15, 2025 by: Business Wire
Sentiment: Neutral
WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio's groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on.
Read More
About Bio-Techne Corporation (TECH)
- IPO Date 1989-02-09
- Website https://www.bio-techne.com
- Industry Biotechnology
- CEO Shane Bohnen
- Employees 3100